Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Search Results

Title:
Pilot study of rituximab and brentuximab vedotin with deferred BMT for relapsed classical Hodgkin lymphoma
Protocol Number:
J1354
Phase:
Pilot
Physician:
Yvette Kasamon
Purpose:
This study investigates a new combination of drugs for treating a first relapse of Hodgkin lymphoma. Rituximab, an antibody drug for non-Hodgkin lymphomas, might attack the â??cancer stem cellâ?? that causes Hodgkin lymphoma. This study adds rituximab to another drug, brentuximab vedotin, which targets Hodgkin/Reed-Sternberg cells. The goal is to try to kill â??cancer stem cellsâ?? as well as the other cancer cells, so that people might avoid riskier treatments like a stem cell transplant.
Eligibility:
To join the study, you must be at least 16 years old, have a first relapse of classical Hodgkin lymphoma (Hodgkin disease), and never have had rituximab or brentuximab vedotin (Adcentris).
Treatment:
Treatment involves up to 8 doses of brentuximab, and up to 10 doses of rituximab. This treatment schedule may change depending on how you are doing: Brentuximab will be given Day 1 of each 21 day (3 week) cycle, for up to 8 cycles. You will first receive brentuximab on Day 1of Cycle 1 and Day 1 of Cycle 2. A PET/CT scan will then be repeated, to see if your lymphoma has decreased. If your lymphoma has decreased enough (either a partial or complete remission) after the first two doses, you will continue with the study treatment; otherwise you will be taken off study. If you continue with the study treatment, brentuximab will continue to be given at the beginning of each cycle (or every 3 weeks) for a total of up to 8 cycles, and also, Rituximab will begin on Day 1 of Cycle 3. The rituximab will be given weekly for 4 weeks, then every three weeks for 4 doses. Then, additional (maintenance) dose of rituximab will be given once every 3 months for two doses.
Population:
Adult
Last Update
09/20/2014 04:03 AM
 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer